Abelacimab, formerly known as MAA868, represents a groundbreaking approach to preventing thrombosis. This antithrombotic agent is a selective monoclonal antibody that prevents the integrin αIIbβ3, a critical player https://aronnzjt719675.pointblog.net/abelacimab-maa868-a-deep-investigation-into-the-new-thrombosis-treatment-92253375